Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Alexander

Showing results (1061-1070 of 1,212) with videos related to

Pageof 122
Sort By:
Occupational and Environmental Medicine|March 21, 2019
Cataract risk in US radiologic technologists assisting with fluoroscopically guided interventional procedures: a retrospective cohort studyRaquel Velazquez-Kronen, David Borrego, Ethel S Gilbert, et al.
Journal of Thrombosis and Haemostasis : JTH|February 5, 2026
Evaluation of the updated ABC-AF-bleeding score 2.0 in patients with atrial fibrillation treated with a direct oral anticoagulant or warfarinZiad Hijazi, Johan Lindbäck, Jonas Oldgren, et al.
British Journal of Pharmacology|March 23, 2024
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in reviewAndreas Papapetropoulos, Stavros Topouzis, Steve P H Alexander, et al.
British Journal of Pharmacology|August 11, 2024
Natural product pharmacology: the British Journal of Pharmacology perspectiveXin Wang, Angelo A Izzo, Andreas Papapetropoulos, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
Circulation|July 28, 2010
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary interventionMauricio G Cohen, Drew A Purdy, Joseph S Rossi, et al.
Circulation|December 10, 2015
Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV TrialRalf E Harskamp, John H Alexander, T Bruce Ferguson, et al.
The American Journal of Cardiology|July 14, 2022
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)Rubina Attar, Angie Wu, Daniel Wojdyla, et al.
The Annals of Thoracic Surgery|February 20, 2007
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgeryAbhinav Goyal, John H Alexander, Gail E Hafley, et al.
Circulation|January 19, 2021
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialZiad Hijazi, John H Alexander, Zhuokai Li, et al.
Pageof 122

Showing results (1061-1070 of 1,212) with videos related to

Sort By:
Pageof 122
Occupational and Environmental Medicine|March 21, 2019
Cataract risk in US radiologic technologists assisting with fluoroscopically guided interventional procedures: a retrospective cohort studyRaquel Velazquez-Kronen, David Borrego, Ethel S Gilbert, et al.
Journal of Thrombosis and Haemostasis : JTH|February 5, 2026
Evaluation of the updated ABC-AF-bleeding score 2.0 in patients with atrial fibrillation treated with a direct oral anticoagulant or warfarinZiad Hijazi, Johan Lindbäck, Jonas Oldgren, et al.
British Journal of Pharmacology|March 23, 2024
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in reviewAndreas Papapetropoulos, Stavros Topouzis, Steve P H Alexander, et al.
British Journal of Pharmacology|August 11, 2024
Natural product pharmacology: the British Journal of Pharmacology perspectiveXin Wang, Angelo A Izzo, Andreas Papapetropoulos, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
Circulation|July 28, 2010
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary interventionMauricio G Cohen, Drew A Purdy, Joseph S Rossi, et al.
Circulation|December 10, 2015
Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV TrialRalf E Harskamp, John H Alexander, T Bruce Ferguson, et al.
The American Journal of Cardiology|July 14, 2022
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)Rubina Attar, Angie Wu, Daniel Wojdyla, et al.
The Annals of Thoracic Surgery|February 20, 2007
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgeryAbhinav Goyal, John H Alexander, Gail E Hafley, et al.
Circulation|January 19, 2021
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialZiad Hijazi, John H Alexander, Zhuokai Li, et al.
Pageof 122